Life Molecular Imaging – Website

Innovative PET imaging agents for earlier and improved diagnosis and better characterization of diseases

Search Icon

Menu Toggle Icon

Skip to content
  • Home
  • About us
    • Leadership Team
    • Partners
    • Business Development & Licensing
    • Compliance & Code of Conduct
    • Contacts
  • Molecular Imaging
    • How It Works
    • Value of Molecular Imaging
  • Research & Development
    • Neuro-Imaging
    • Onco-Imaging
    • Cardiovascular-Imaging
  • Products
  • News
    • Current News
    • Careers

Life Molecular Imaging Receives Orphan Drug Designations for its Tau Tracer PI-2620 as Diagnostic Tool for Progressive Supranuclear Palsy and Corticobasal Degeneration

20. May 202120. May 2021lifemolecular

Click here to read more: Press release

Post navigation

← Life Molecular Imaging announces an ongoing collaboration with UCB for
PI-2620, a novel tau imaging agent, for improved diagnosis of Progressive Supranuclear Palsy
DuChemBio Co., Ltd. & Life Molecular Imaging Announce Material Transfer And Clinical Supply Agreement for [18F]PI-2620 Tau PET Tracer →
© Copyright 2018 Life Molecular Imaging
Data Protection & Cookies. Our site uses cookies.
Click here to learn more: Data protection
Imprint / Data protection
Contact
Scroll to Top